Uwe Siebert, MD, MPH, MSc, ScD

Chair of the Department of Public Health and Health Technology Assessment at UMIT, Austria Uwe Siebert
Adjunct Professor of Health Policy and Management
Director of the Division for Public Health Decision Modeling, HTA, and Health Economics in the ONCOTYROL – Center for Personalized Cancer Medicine, Austria

Uwe Siebert has an adjunct appointment as Professor of Health Policy and Management at the Harvard Chan School of Public Health. He is also Professor of Public Health and health Technology Assessment and the Chair of the Department of Public Health, Health Services Research and Health Technology Assessment at UMIT - University for Health Sciences, Medical Informatics and Technology in Hall/Innsbruck, Austria.

His research interests include applying evidence-based quantitative and translational methods from public health, epidemiology, comparative effectiveness research, health services and outcomes research, economic evaluation and decision sciences in the framework of health technology assessments (HTA) as well as in the clinical context of routine health care. His current substantive research focuses on cancer, cardiovascular disease, hepatitis C, and others. His methodological research includes evaluations of public health interventions, diagnostic imaging procedures, personalized medicine, causal inference from “big” data, decision-analytic modelling, and study designs controlling for treatment switching. He is the course director of the Harvard summer course on ‘Decision Analysis in Clinical Research’ and he teaches courses in decision-analytic modeling, HTA, economic evaluation, analysis of big data, and advanced causal epidemiologic methods at several universities and for industry in Europe, USA, South America, and Asia.

He is a past Vice President of the Society of Medical Decision Making (SMDM) and a member of several national and international Directors and Trustees Boards. He has served as member of the ISPOR Board of Directors and member of the International Expert Committee Advising the Institute for Quality and Efficiency in Health Care (IQWiG) on Methods for Economic Evaluations. He is Clinical Guideline Commissioner for the Association of the Scientific Medical Societies in Germany (AWMF), Co-Chair of the ISPOR-SMDM Modeling Good Research Practices Task Force, Co-Chair of the ‘Issues in Methodology Section’ of the SMDM Policy Initiative, and a Leadership Member of the ISPOR Personalized/Precision Medicine Special Interest Group. He has worked with several HTA Agencies (e.g., DAHTA@DIMDI/Germany, IQWiG/Germany, NICE/UK, ANVISA/Brazil, CADTH/Canada, LBI-HTA/Austria, GOEG/Austria) and he advises government agencies, academic institutions and industry regarding the conduction and impact of health technology assessments on policy and reimbursement decisions. He has authored more than 300 publications and is Associate Editor of the International Journal of Public Health as well as editorial board member of several scientific journals.

Publications

  • Schiller-Frühwirth, I. C., Jahn, B., Arvandi, M. & Siebert, U. (2017). Cost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review.. Applied health economics and health policy, . [Online version]
  • Schnell-Inderst, P., Iglesias, C. P., Arvandi, M., Ciani, O., Gothe, R. M., Peters, J., Blom, A. W., Taylor, R. S. & Siebert, U. (2017). A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement.. Health economics, 26 Suppl 1, 46-69. [Online version]
  • Stenehjem, D. D., Bellows, B. K., Yager, K. M., Jones, J., Kaldate, R., Siebert, U. & Brixner, D. I. (2016). Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.. Oncologist, 21(2), 196-204. [Online version]
  • Stenehjem, D. D., Bellows, B. K., Yager, K. M., Jones, J., Kaldate, R., Siebert, U. & Brixner, D. I. (2015). Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.. Oncologist, . [Online version]
  • Rochau, U., Vukicevic, D., Schmidt, S., Stenehjem, D., Brixner, D., Radich, J., Gastl, G. & Siebert, U. (2015). Cost-Effectiveness Analysis On Starting Patients With Chronic Myeloid Leukemia On A Highly Potent Tyrosine Kinase Inhibitor And Early Switching To Imatinib.. Value Health, 18(7), A462. [Online version]